© Reuters. PHOTOS: Exterior view of GlaxoSmithKline (GSK) headquarters in Brentford, London, Britain, May 4, 2020. REUTERS / Matthew Childs
By Mrinmay Dey and Siddharth Cavale
(Reuters) – Consumer Unilever (NYSE 🙂 stock chart is approaching Glaxosmithkline (LON 🙂 on the purchase of medical equipment, after a newspaper reported that $ 50 billion ($ 68.4 billion) in production had been rejected.
Unilever, which has been criticized by some money sellers for the group’s low price, confirmed its approach to the business in a statement on Saturday.
“GSK Consumer Healthcare is a leader in consumer health and it can be very positive as Unilever continues to redefine its reputation,” he said.
“There can be no guarantee that any agreement will be fulfilled.”
GSK declined to comment.
Earlier, Britain’s Sunday Times reported that Unilever’s bid for a business venture at the end of last year was worth £ 50 billion, and was rejected by GSK and Pfizer (NYSE :), who has a small stake in this section.
The Unilever method, which includes colors such as Dove and Marmite soap, Glaxo’s portfolio of home brands including Panadol painkillers and Sensodyne toothpaste sounded unsolicited, it added.
Unilever’s request did not include funding for purchasing or approving synergies, the newspaper said, adding that it was unclear whether the group would pay more.
Unilever has been pressured by investors after a stint in sports such as Procter & Gamble (NYSE :).
Chief Executive Alan Jope recently had a falling out with British fund manager Terry Smith, who criticized the group for promoting established policies based on performance.
Brokerage Jefferies last year set the total value of all buyers at £ 45 billion.
Deutsche Bank (DE:
Unilever has already hinted at the idea that it was in the big retail market. Jope has said that he only prefers small, button-bought items in fast-growing areas such as high-quality beauty and health and wellness.
($ 1 = 0.7314 pounds)
Fusion Media or anyone involved with Fusion Media would not accept any liability for any loss or damage as a result of reliance on information including data, documents, charts and buy / sell tokens contained within this website. Please know more about the risks and costs associated with trading the financial markets, this is one of the most risky ways to earn money.